The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
- PMID: 15166778
- DOI: 10.1097/00041433-200406000-00002
The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
Abstract
Purpose of review: Apolipoprotein (apo)CIII and apoAV play an important role in triglyceride metabolism as evidenced by the unambiguous and opposing phenotypes of transgenic and knockout mouse models. In this review we discuss studies on the genetics, protein structure, and regulation of apoCIII and apoAV and compare their potential molecular mechanisms of action in triglyceride metabolism. We examine the hypothesis that apoCIII and apoAV synergistically affect triglyceride metabolism.
Recent findings: It has now been firmly established that variation in plasma triglyceride levels in a wide range of human populations is strongly associated with genetic variation at the chromosomal locus encoding both the APOC3 and APOA5 genes, the APOA1/C3/A4/A5 gene cluster. The close physical linkage of these genes and the frequent concurrence of genetic variants, however, complicate the assignment of specific metabolic defects to specific polymorphisms. Recent insight into the regulation of APOC3 and APOA5 gene expression and structural modeling studies on the apoAV protein have provided novel clues for the potential molecular mechanisms responsible for the effects of apoCIII and apoAV on triglyceride metabolism.
Summary: Hypertriglyceridemia is a major independent risk factor in the development of cardiovascular disease. Moreover, triglyceride-derived fatty acids are thought to play a key role in the development and progression of the metabolic syndrome. As modulators of triglyceride metabolism, apoCIII and apoAV are key players and potential therapeutic targets. However, little is known of their molecular mechanism and potential cooperativity. Rational therapeutic application will require the filling of this hiatus in our knowledge.
Similar articles
-
Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.Atherosclerosis. 2007 Oct;194(2):287-92. doi: 10.1016/j.atherosclerosis.2006.12.010. Epub 2007 Jan 12. Atherosclerosis. 2007. PMID: 17222847 Review.
-
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Ann Med. 2006;38(1):2-10. doi: 10.1080/07853890500407488. Ann Med. 2006. PMID: 16448983 Review.
-
SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population.Atherosclerosis. 2006 Apr;185(2):353-60. doi: 10.1016/j.atherosclerosis.2005.06.043. Epub 2005 Aug 25. Atherosclerosis. 2006. PMID: 16125709
-
The expression of intact and mutant human apoAI/CIII/AIV/AV gene cluster in transgenic mice.J Biol Chem. 2005 Apr 1;280(13):12559-66. doi: 10.1074/jbc.M409883200. Epub 2005 Jan 13. J Biol Chem. 2005. PMID: 15649902
-
Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice.Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1297-302. doi: 10.1161/01.ATV.0000130463.68272.1d. Epub 2004 Apr 29. Arterioscler Thromb Vasc Biol. 2004. PMID: 15117734
Cited by
-
FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.Aging (Albany NY). 2024 Mar 3;16(5):4095-4115. doi: 10.18632/aging.205610. Epub 2024 Mar 3. Aging (Albany NY). 2024. PMID: 38441531 Free PMC article.
-
The pathogenic mutations of APOA5 in Chinese patients with hyperlipidemic acute pancreatitis.Lipids Health Dis. 2024 Feb 8;23(1):44. doi: 10.1186/s12944-024-02011-5. Lipids Health Dis. 2024. PMID: 38331899 Free PMC article.
-
Metabolomic analysis of vascular cognitive impairment due to hepatocellular carcinoma.Front Neurol. 2023 Mar 16;13:1109019. doi: 10.3389/fneur.2022.1109019. eCollection 2022. Front Neurol. 2023. PMID: 37008043 Free PMC article.
-
ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/STAT3 Pathway in OSCC.Int J Mol Sci. 2022 Oct 24;23(21):12777. doi: 10.3390/ijms232112777. Int J Mol Sci. 2022. PMID: 36361568 Free PMC article.
-
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?Curr Atheroscler Rep. 2021 Jun 19;23(8):40. doi: 10.1007/s11883-021-00936-1. Curr Atheroscler Rep. 2021. PMID: 34146170 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous